FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547181837> ?p ?o ?g. }

• W2547181837 endingPage "5286" @default.
• W2547181837 startingPage "5286" @default.
• W2547181837 abstract "Abstract OBJECTIVE: The aim of this study was to investigate the clinical biological features, treatment strategy, prognosis and long-term survival in children with acute promyelocytic leukemia（APL）. Focus on the effect of stratified therapy in childhood APL. METHODS: The clinical data of 42 cases of APL with t (15;17) from April 2004 to December 2012 were analyzed retrospectively. Patients were stratified into three risk-group based on white blood cell count and platelet count at diagnosis: standard, intermediate and high-risk group. Induction treatment consisted of all-trans retinoic acid（ATRA）and Idarubicin（IDA）), followed by multi-drug chemotherapy consolidation and a long term maintenance therapy including ATRA,6-Mercaptopurine（6-MP), Methotrexate（MTX）. The complete remission (CR) rate, overall survival (OS) rate, disease free survival (DFS) rate, hematologic and cytogenetic cumulative incidence of relapse (CIR) were compared among the three groups, the stratified therapy in childhood APL and its correlation with clinical prognosis was analyzed. The statistical analyses were performed by SPSS. RESULTS: 42 patients were enrolled (median age 5.8 years, range 1.5-14, 64% males and 36% females), 11 in standard-risk group, 18 in intermediate-risk group, 13 in high-risk group. Immunophenotyping analysis indicated that MPO, CD33, CD13 and CD117 were commonly expressed antigens while HLA-DR and CD34 were mostly the negative markers on APL cells. Of the 42 patients receiving treatment, 38 children (90.5%) achieve complete remission. 1 patient from the high risk group died of intracranial hemorrhage, 1 patient from the Standard Risk group died of anthracycline cardiotoxicity, 1 patient from the intermediate group died of severe infection. The estimated overall survival (OS) rates at 3 and 5 years were （74.2±6.7%）and（70±7.4%）respectively, the disease free survival (DFS) rates were（71±3.8%）and（57±8.1%）respectively. The 3 and 5-year cumulative incidence of relapse (CIR) were 18% and 27%. OS for three groups were (86±7.4%),（71±4、8%）and（57±4.7%）respectively, the 5-year DFS were (82±6.3%), (61±5.3%)and(50±7.2%) and 5-year CIR were 6.7%、18%、35%.There were significant differences in 5-year OS, DFS and CIR rates of three groups (P< 0.05). CONCLUSION: The results indicated that ATRA combined with Anthracycline is effective and safe for treatment of newly diagnosed childhood APL. Prognosis of childhood APL was associated with clinical types. It indicates that stratified therapy according to different risk group can improve the OS and EFS rate and decrease the CIR rate while minimizing chemotherapy-related toxicity. Now, real-time quantitative polymerase chain reaction (RQ-PCR), which can performed to detect PML-RARα fusion transcripts, has become an important means for minimal residual disease (MRD) assays, but it is rarely used in children. Compared with RQ-PCR, clinical risk-adapted classification is a simple, validated and highly predictive index for the determination of stratified therapy in childhood acute promyelocytic leukemia. Disclosures No relevant conflicts of interest to declare." @default.
• W2547181837 created "2016-11-11" @default.
• W2547181837 creator A5003088149 @default.
• W2547181837 creator A5029079863 @default.
• W2547181837 creator A5039583318 @default.
• W2547181837 creator A5053758977 @default.
• W2547181837 creator A5059515609 @default.
• W2547181837 creator A5064840674 @default.
• W2547181837 date "2014-12-06" @default.
• W2547181837 modified "2023-09-28" @default.
• W2547181837 title "Clinical Investigation of Stratified Therapy in Childhood Acute Promyelocytic Leukemia" @default.
• W2547181837 doi "https://doi.org/10.1182/blood.v124.21.5286.5286" @default.
• W2547181837 hasPublicationYear "2014" @default.
• W2547181837 type Work @default.
• W2547181837 sameAs 2547181837 @default.
• W2547181837 citedByCount "1" @default.
• W2547181837 countsByYear W25471818372015 @default.
• W2547181837 crossrefType "journal-article" @default.
• W2547181837 hasAuthorship W2547181837A5003088149 @default.
• W2547181837 hasAuthorship W2547181837A5029079863 @default.
• W2547181837 hasAuthorship W2547181837A5039583318 @default.
• W2547181837 hasAuthorship W2547181837A5053758977 @default.
• W2547181837 hasAuthorship W2547181837A5059515609 @default.
• W2547181837 hasAuthorship W2547181837A5064840674 @default.
• W2547181837 hasBestOaLocation W25471818371 @default.
• W2547181837 hasConcept C104317684 @default.
• W2547181837 hasConcept C126322002 @default.
• W2547181837 hasConcept C141071460 @default.
• W2547181837 hasConcept C185592680 @default.
• W2547181837 hasConcept C2776601000 @default.
• W2547181837 hasConcept C2778041864 @default.
• W2547181837 hasConcept C2778461978 @default.
• W2547181837 hasConcept C2779117419 @default.
• W2547181837 hasConcept C2781121885 @default.
• W2547181837 hasConcept C2911091166 @default.
• W2547181837 hasConcept C55493867 @default.
• W2547181837 hasConcept C71924100 @default.
• W2547181837 hasConcept C88879693 @default.
• W2547181837 hasConcept C90924648 @default.
• W2547181837 hasConceptScore W2547181837C104317684 @default.
• W2547181837 hasConceptScore W2547181837C126322002 @default.
• W2547181837 hasConceptScore W2547181837C141071460 @default.
• W2547181837 hasConceptScore W2547181837C185592680 @default.
• W2547181837 hasConceptScore W2547181837C2776601000 @default.
• W2547181837 hasConceptScore W2547181837C2778041864 @default.
• W2547181837 hasConceptScore W2547181837C2778461978 @default.
• W2547181837 hasConceptScore W2547181837C2779117419 @default.
• W2547181837 hasConceptScore W2547181837C2781121885 @default.
• W2547181837 hasConceptScore W2547181837C2911091166 @default.
• W2547181837 hasConceptScore W2547181837C55493867 @default.
• W2547181837 hasConceptScore W2547181837C71924100 @default.
• W2547181837 hasConceptScore W2547181837C88879693 @default.
• W2547181837 hasConceptScore W2547181837C90924648 @default.
• W2547181837 hasIssue "21" @default.
• W2547181837 hasLocation W25471818371 @default.
• W2547181837 hasOpenAccess W2547181837 @default.
• W2547181837 hasPrimaryLocation W25471818371 @default.
• W2547181837 hasRelatedWork W2030489655 @default.
• W2547181837 hasRelatedWork W2080533166 @default.
• W2547181837 hasRelatedWork W2125294002 @default.
• W2547181837 hasRelatedWork W2136772335 @default.
• W2547181837 hasRelatedWork W2159967007 @default.
• W2547181837 hasRelatedWork W2170968449 @default.
• W2547181837 hasRelatedWork W2522239190 @default.
• W2547181837 hasRelatedWork W2531725250 @default.
• W2547181837 hasRelatedWork W2552003416 @default.
• W2547181837 hasRelatedWork W2979449081 @default.
• W2547181837 hasVolume "124" @default.
• W2547181837 isParatext "false" @default.
• W2547181837 isRetracted "false" @default.
• W2547181837 magId "2547181837" @default.
• W2547181837 workType "article" @default.